JULIE ZULKOSKY: Open Payments
NPI 1184214801 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,450 in 173 payments from 17 companies in 2025. Trend: 2023 $2,116 · 2024 $1,552 · 2025 $2,450
Food & beverage: $2,450
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 28 | $450 |
| Otsuka America Pharmaceutical, Inc. | 26 | $322 |
| Vanda Pharmaceuticals Inc. | 20 | $317 |
| ABBVIE INC. | 29 | $305 |
| Axsome Therapeutics, Inc. | 22 | $302 |
| Lundbeck LLC | 9 | $171 |
| Alkermes, Inc. | 15 | $146 |
| E.R. Squibb & Sons, L.L.C. | 6 | $101 |
| Noven Therapeutics, LLC | 4 | $67 |
| Janssen Pharmaceuticals, Inc | 3 | $59 |
Products named: CAPLYTA, REXULTI, Auvelity, VRAYLAR, FANAPT, ABILIFY ASIMTUFII, ARISTADA, COBENFY.
Industry payments across NE — which companies pay providers there.
